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A B S T R A C T
This is a protocol for a Cochrane Review (Diagnostic test accuracy). The objectives are as follows:
To estimate the sensitivity and specificity of each technique for determining 1p/19q codeletion status in glioma, with a view to
determining the most sensitive and specific technique(s).
B A C K G R O U N D
Gliomas are a type of brain tumour. There are different types of
glioma. Gliomas may have changes in their genetic information
that can help identify the specific type of glioma that is present.
These changes can also give information about the likely outcomes
of glioma, for example how likely it is to respond to a particular
treatment. One of the possible changes that may be present is
the loss of parts of chromosome 1 and chromosome 19, which is
called codeletion of chromosomal arms 1p and 19q. In this review
we aim to determine the most accurate way of testing whether a
glioma has codeletion of chromosomal arms 1p and 19q.
Target condition being diagnosed
Gliomas are a type of brain tumour that are thought to arise from
progenitor cells in the central nervous system and they share some
features with glial cells. Glial cells are the cells that support and in-
sulate neurons. Age-adjusted incidence rates for all gliomas (ICD-
O-3 morphology codes 9380-9480) range from 4.67 to 5.73 per
100,000 persons (Ostrom 2014), with varied survival rates. A re-
view of population-based studies found that pilocytic astrocytoma
(World Health Organization (WHO) grade I) has the highest five-
year relative survival rate, varying between 57.3% and 97.3%;
whilst glioblastoma (WHO grade IV) has the poorest survival with
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only 0.05% to 8.9% of people surviving five years after diagnosis
(Ostrom 2014).
Complete deletion of both the short arm of chromosome 1 (1p)
and the long arm of chromosome 19 (19q) (1p/19q codeletion) is
a mutation that can occur in gliomas. The codeletion is thought
to be an early event in the development of cancer (Pinkham
2015), and is thought to be a result of an unbalanced whole-arm
translocation between chromosomes 1 and 19 with the loss of
the resulting hybrid chromosome (Griffin 2006; Jenkins 2006).
As described below, the codeletion has diagnostic, prognostic and
predictive abilities in glioma.
According to the WHO, the diagnosis of oligodendroglioma (a
subtype of glioma) and anaplastic (high-grade) oligodendroglioma
requires the demonstration of both an isocitrate dehydrogenase
(IDH) gene family mutation and 1p/19q codeletion (Louis 2016).
A recent systematic review and meta-analysis of the prognostic
value of chromosomal 1p/19q codeletion in low-grade (WHO
grade II) and high-grade/anaplastic (WHO grade III) tumours
found a pooled hazard ratio (HR) for mortality of 0.28 (95 %
confidence Interval (CI) 0.13 to 0.62; 9 studies) favouring 1p/19q
codeletion after adjusting for age, extent of resection, IDH-1 mu-
tation and type of therapy (Hu 2016). Another systematic review
and meta-analysis that evaluated the association between codele-
tion of 1p/19q and overall survival among people with different
grades and subtypes of gliomas found that 1p/19q codeletion was
associated with increased overall survival (HR 0.43; 95% CI 0.35
to 0.53; 14 studies) (Zhao 2014). Similar results were seen in both
low-grade tumours (HR 0.45; 95% CI 0.30 to 0.68; 5 studies) and
high-grade gliomas (HR 0.41; 95% CI 0.31 to 0.53; 6 studies).
Similar results were also seen for astrocytic tumours (HR 0.52;
95% CI 0.36 to 0.75; 3 studies) and oligodendroglial tumours
(HR 0.41; 95% CI 0.30 to 0.56; 9 studies) (Zhao 2014). In this
review they also found that there was no difference in the HR for
overall survival between studies utilising two different techniques
(Polymerase Chain Reaction (PCR) and Fluorescence in situ hy-
bridization (FISH)) to assess the status of chromosomal arms 1p
and 19q (Zhao 2014).
1p/19q codeletion also predicts response to chemotherapy in
anaplastic oligodendrogliomas. The European Organisation for
Research and Treatment of Cancer (EORTC) study 26951 was
a phase III trial comparing radiotherapy (RT) with RT plus
adjuvant chemotherapy with procarbazine, lomustine and vin-
cristine (PCV) in people with newly diagnosed anaplastic oligo-
dendroglioma (Van Den Bent 2013). An exploratory analysis of
the long-term follow-up found that there was a trend towards
more benefit, in terms of increased survival, from adjuvant PCV in
people with 1p/19q codeletion. In people with 1p/19q codeletion
fewer than half of the people died during follow-up in the RT plus
PCV group (and therefore median overall survival was not reached)
versus a median survival of 112 months in the RT group (HR
0.56, 95% CI 0.31 to 1.03) (Van Den Bent 2013). In people with
nondeleted 1p/19q, median overall survival was 25 months in the
RT plus PCV group versus 21 months in the RT group (HR 0.83,
95% CI 0.62 to 1.10) (Van Den Bent 2013). Similarly, long-term
follow-up of the Radiation Therapy Oncology Group (RTOG)
study 9402, which also compared PCV plus RT with RT alone
in people with pure and mixed anaplastic oligodendrogliomas,
found that the median survival of those with codeleted tumours
treated with PCV plus RT was twice that of people receiving RT
(14.7 versus 7.3 years; HR 0.59; 95% CI, 0.37 to 0.95; P = 0 .03)
(Cairncross 2013). For those with non-codeleted tumours, there
was no difference in median survival by treatment arm (2.6 versus
2.7 years; HR 0.85; 95% CI, 0.58 to 1.23; P = 0.39) (Cairncross
2013).
1p/19q codeletion can be absolute, or relative if it occurs in the
presence of polysomy (when cells contain at least one more copy
of a chromosome than normal) or polyploidy (when cells con-
tain more than two sets of chromosomes). Several studies have
suggested that people with 1p/19q codeletions in the presence
of polysomy or polyploidy have a worse prognosis (progression
free survival or overall survival) than people with absolute 1p/19q
codeletions, with some studies suggesting that prognosis may be
similar to that of people with no codeletion (Chamberlain 2015;
Jiang 2014; Ren 2013; Snuderl 2009). In all these studies, classifi-
cation of polysomy occurred when more than 30% of nuclei had
more than two 1q and 19p signals, as assessed by FISH. Although
there are limitations to these studies, for example treatment was
not standardised, these findings have led us to conclude that we
are only interested in diagnosing absolute deletions.
We are also interested in diagnosing situations where one copy of
1p/19q has been lost and the other copy duplicated (also termed
copy-neutral loss of heterozygosity (LOH)).
Index test(s)
This review will assess the sensitivity and specificity of any DNA-
based techniques that can be used on tumour tissue to directly
evaluate 1p/19q codeletion status. These include the following.
• FISH
• Chromogenic in situ hybridization (CISH)
• PCR-based LOH assays (also known as PCR-based - short
tandem repeat or microsatellite analysis)
• Restriction fragment length polymorphism (RFLP) analysis
• Comparative quantitative PCR
• Multiplex-ligation-dependent probe amplification (MLPA)
• Comparative genomic hybridization (CGH)
• CGH arrays (aCGH)
• Single Nucleotide Polymorphism (SNP) arrays
• Methylation arrays
• Next-generation sequencing (NGS)
Unfortunately, there is no perfect (100% sensitive, 100% specific)
’gold standard’ test for 1p/19q codeletion status: each of the above
tests could theoretically produce false-positive and/or false-neg-
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ative results. These techniques are briefly described in Table 1,
along with the theoretical ways in which false-positive and false-
negative results could be obtained.
Clinical pathway
Prior test(s)
Before testing for 1p/19q codeletion status, tumours undergo his-
tological assessment. 1p/19q status is determined in tumours as-
sessed to be gliomas by histology, as depicted in Figure 1.
Figure 1. Testing which occurs prior to determination of 1p/19q status
Role of index test(s)
As described previously, the codeletion has diagnostic, prognostic
and predictive abilities in glioma.
Alternative test(s)
All DNA-based techniques which are used to determine 1p/19q
status in tumour tissue will be eligible.
Rationale
European guidelines recommend that 1p/19q status is evaluated
to support a diagnosis of oligodendroglioma and for prognosis,
and that treatment decisions are based on the 1p/19q status (Stupp
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2014; Weller 2017). WHO guidelines require the demonstration
of both an IDH mutation and 1p/19q codeletion for the diagnosis
of oligodendroglioma and anaplastic oligodendroglioma (Louis
2016). Recent guidance from the National Institute for Health and
Care Excellence (NICE) recommend testing 1p/19q codeletion to
identify oligodendrogliomas, and the adjuvant chemotherapeutic
recommended after surgery for people with grade III glioma varies
according to 1p/19q status (NICE 2018).
However, there are several different methods for determining 1p/
19q status and no clear consensus regarding the optimal method.
The two most common methods for routine diagnostic use are
FISH- and PCR-based LOH assays (Woehrer 2015). In the 2017
UK Cytogenomic External Quality Assessment Service (CEQAS)
report, of the 35 enrolled laboratories 25 laboratories used FISH,
one laboratory used MLPA, four laboratories used arrays and one
laboratory used quantitative PCR.
This review will go some way to answering the question “Do
molecular subtyping techniques improve treatment selection, pre-
diction and prognostication in people with brain and spinal cord
tumours?”, one of the top 10 topics identified by the James Lind
Alliance Neuro-Oncology Priority Setting Partnership (James Lind
Alliance). The National Cancer Research Institute Brain Clinical
Studies Group has identified this as an area for future research.
A final element of the review will be to consider the costs, and
cost-effectiveness of alternative methods of assessing 1p/19q sta-
tus. Each method of 1p/19q assessment will incur costs, such as
laboratory costs, clinic costs and subsequent treatment costs. The
benefits of targeting treatment may include greater survival and
less exposure to potentially toxic treatments, as well as potential
cost-savings from the avoidance of waste from more efficient use
of scarce health services resources.
O B J E C T I V E S
To estimate the sensitivity and specificity of each technique for
determining 1p/19q codeletion status in glioma, with a view to
determining the most sensitive and specific technique(s).
Secondary objectives
If sufficient studies are identified, we aim to break down each
technique by relevant features, for example the region analysed/
probes used and the cut-off used to classify 1p/19q status.
To critically appraise and summarise current evidence on the re-
source use, costs and cost-effectiveness of techniques for deter-
mining 1p/19q status in gliomas (conduct a full integrated review
of economic evidence) and assess the cost-effectiveness of the dif-
ferent approaches of determining 1p/19q status using a decision
model.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Types of studies for diagnostic test accuracy (DTA) review
Cross-sectional studies that use two or more tests to assess 1p/19q
status in tumour tissue from the same set of people.
Types of studies for the full integrated review of economic
evidence
Cost and full economic evaluations (cost-effectiveness analyses,
cost-utility analyses and cost-benefit analyses) conducted alongside
any study designs or as part of a modelling exercise.
Participants
Adults ( ≥ 18 years old) with glioma.
Index tests
• Any DNA-based technique which is used to determine 1p/
19q status in tumour tissue.
• Studies which assess 1p/19q status by
immunohistochemistry will be excluded.
• Studies that assess 1p/19q status from blood samples or by
imaging (i.e. magnetic resonance imagining, computed
tomography, positron emission tomography) will be excluded.
Target conditions
Absolute 1p/19q codeletion (1p/19q codeletion in the absence of
polysomy).
Reference standards
As described in Table 1, each of the tests can potentially generate
false-positive and false-negative results. As such, there is no true
’gold standard’ reference test. In order to estimate the sensitivity
and specificity of each test, we will perform three separate sets of
statistical analyses.
• Using FISH as the reference standard, i.e. assuming that
FISH has 100% sensitivity and specificity
• Using PCR-based LOH assays as the reference standard, i.e.
assuming that PCR-based LOH assays have 100% sensitivity
and specificity
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• No reference standard. Using latent class methodology, it is
possible to estimate the sensitivity and specificity of a number of
tests without making the strong assumption that any one test is
100% sensitive and 100% specific. Further details are provided in
the ’Statistical analysis and data synthesis - DTA review’ section.
Search methods for identification of studies
Electronic searches
Electronic searches for the DTA review
We will search MEDLINE Ovid (from 1946 to current date),
Embase Ovid (from 1980 to current date) and BIOSIS Citation
Index (from 1969 to current date). The search strategies are given
in Appendix 1.
We will also search for studies available in PubMed that are not
available in MEDLINE using the syntax ’pubmednotmedline[sb]’.
There will be no restrictions based on language or date of publi-
cation.
Electronic searches for the full integrated review of
economic evidence
Searches for economic evaluation studies will be performed in
MEDLINE and Embase from April 2015. The NHS Economic
evaluation database (EED) will also be searched up to the end of
March 2015, when the last records were added to that database.
NHS EED was based on a comprehensive search of bibliographic
databases including MEDLINE and Embase so searches of MED-
LINE and Embase before 1st April 2015 are not required.
Searching other resources
Searching other resources for the DTA review
We will search Open Grey (http://www.opengrey.eu/) using the
free text terms from our MEDLINE search (((“chromosome 1”
OR 1p) AND (“chromosome 19” OR 19q)) OR (1p19q OR
“1p/19q” OR (1p* NEAR/3 19q*))) AND (glioma* OR astro-
cytoma* OR astroblastoma* OR ependymoma* OR subependy-
moma* OR oligodendroglioma* OR oligoastrocytoma* OR pleo-
morphic xanthoastrocytoma* OR glioblastoma* OR GBM* OR
ganglioglioma* OR gliosarcoma* OR gangliocytoma* OR ((glial*
OR glioneuronal* OR brain*) AND (tumor* OR tumour* OR
cancer* OR neoplasm*))).
We will search for relevant material in dissertations and the-
ses using ProQuest Dissertations & Theses Global (https://
search.proquest.com/pqdtglobal/dissertations/), using the same
strategy as for Open Grey but limiting to all fields except full text.
We will also search the Networked Digital Library of Theses and
Dissertations (http://search.ndltd.org/index.php).
The Society of Neuro-Oncology (SNO) and its partner associa-
tions the EANO and The Japan Society of Neuro-Oncology hold
meetings where relevant research may be presented. We will search
for abstracts from these meetings and other relevant conferences
via the Web of Science Conference Proceedings Citation Index
(CPCI-S) (from 1990 to current date). We will translate the BIO-
SIS search for CPCI-S as both databases are hosted on Web of
Science.
We will also search for any ongoing studies via the WHO Inter-
national Clinical Trials Registry Platform (ICTRP). The search
strategy is given in Appendix 1.
We will examine the reference lists of included studies, and of any
systematic reviews that we identify.
Searching other resources for the full integrated review of
economic evidence
Relevant grey literature (such as health technology assessments,
reports and working papers) will also be considered for inclusion.
Data collection and analysis
Selection of studies
Selection of DTA studies
Two review authors will independently screen titles and abstracts.
All articles deemed to be relevant by either review author, or whose
relevance cannot be determined from the abstract, will be retrieved.
Full-text articles will then be independently screened in duplicate.
Disagreements will be resolved by consensus, with discussion with
a third review author if necessary.
Selection of economic studies
We will include full economic evaluation studies alongside any
type of study design, model-based evaluations and cost-analysis
will be included. For the search for economic studies, two review
authors (Luke Vale (LV) and Ashleigh Kernohan (AK)) will inde-
pendently screen for, identify and classify eligible studies.
The scope of this review includes multiple types of test for codele-
tion of chromosomal arms 1p and 19q (e.g. FISH, CISH). As a
result, studies which evaluate single strategies of detection or com-
pare multiple strategies will be included.
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Data extraction and management
Two review authors will independently perform data extraction
using a data extraction form. Disagreements will be resolved by
consensus, with discussion with a third review author if necessary.





• Whether the study compared two or compared multiple
techniques for determining 1p/19q status
Population characteristics
• Number of participants
• Population source and setting
• Inclusion/exclusion criteria




• Karnofsky performance status
• First diagnosis or recurrent disease
• Prevalence of 1p/19 codeletion
Index tests (per test performed)
• Technique
• Tumour sample type (i.e. formalin-fixed and paraffin-
embedded (FFPE) or frozen tissue)
• Region(s) analysed
• Cut-off/threshold used to determine 1p/19q status
• Method of determining threshold and whether it was pre-
specified
Raw test result data
We will present the raw data from each individual study as a con-
tingency table of cross-classified test results. For studies comparing
two tests, this will be a 2 x 2 table. Regardless of whether the study
treated one of the tests as a reference standard, we will not consider
results to be true positives but rather ’positive on both tests’; not
true negatives but rather ’negative on both tests’; not false positives
but rather ’positive on test A and negative on test B’; and not false
negatives but rather ’negative on test A and positive on test B’. In
situations where more than two tests are compared the data will
form tables of higher dimensions. For example, if three tests are
compared then the table formed will be 2 x 2 x 2, i.e. eight cells
of cross-classified results.
A data extraction form for economic evaluations will be developed
based on the format and guidelines used to produce structured
abstracts of economic evaluations for inclusion in the NHS Eco-
nomic Evaluation Database (NHS EED), adapted to the specific
requirements of this review. The following data will be collected
from the economic evaluation studies.
• Type of evaluations
• Sources of effectiveness data
• Cost data
• Sources of cost data
• Sources of outcome valuations
• Analytical approach
Assessment of methodological quality
Assessment of methodological quality in included DTA
studies
We will assess applicability and risk of bias of included studies in-
dependently and in duplicate using the QUADAS-2 tool (Whiting
2011). Disagreements will be resolved by consensus, with discus-
sion with a third review author if necessary. We have tailored the
tool to our review, and the tailored form of the tool, along with
how we will judge risk of bias and applicability in each study is
described in Appendix 2.
Assessment of methodological quality in included economic
studies
Economic evaluation studies will be assessed for bias in two stages.
The first stage will involve assessing risk of bias from the sources of
the effectiveness data. If the economic evaluation is model-based
then the ROBIS tool will be used to assess bias in the effectiveness
studies (Whiting 2016). The second stage assessing the economic
evaluations for bias is to assess the overall methodological quality
of the economic component of the evaluation. Evaluations carried
out alongside studies will be assessed using the CHEERS checklist
(Husereau 2013) and model-based economic evaluations will be
assessed using the NICE methodology checklist (NICE 2012).
Statistical analysis and data synthesis
Statistical analysis and data synthesis for the DTA review
As described above (‘Reference standards’ section), we will perform
three separate analyses.
• Using FISH as the reference standard
• Using PCR-based LOH assays as the reference standard
• Latent class analysis
If the results obtained using the three approaches differ, we will
prefer the results of the latent class analysis. This is because we do
not believe the key assumption underlying analyses (1) and (2) -
that either FISH or PCR-based LOH assays are 100% sensitive
and 100% specific - to be plausible (see Table 1).
For analyses 1 and 2, we will perform bivariate meta-analyses of the
sensitivity and specificity of each index test where possible, assum-
ing binomial likelihoods for the number of ’true positive’ and ’true
negative’ test results (Chu 2006; Reitsma 2005). This approach
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allows for heterogeneity in sensitivity and specificity across studies
and for between-study correlation in these measures. The bivariate
meta-analysis model can be used to produce summary operating
points (summary sensitivities and specificities) with 95% confi-
dence, or credible regions and prediction regions. Drawing on the
equivalence of the bivariate model and the hierarchical summary
receiver operating characteristic (HSROC) model (Rutter 2001)
in the absence of covariates, the bivariate model can also be used
to produce summary receiver operating characteristic (SROC)
curves (Arends 2008; Harbord 2007). For tests where commonly
used thresholds are reported, we will produce summary operat-
ing points. If thresholds differ between studies, we will produce
SROC curves. If a study contributes 2 x 2 contingency tables for
different thresholds, we will consider using one of the recently de-
veloped extensions to the bivariate meta-analysis model that can
accommodate such data (Jones 2018; Steinhauser 2016).
It is anticipated, however, that there will be few studies that com-
pare the same index test with FISH or PCR-based LOH assays.
We therefore do not expect to be able to estimate distinct be-
tween-study heterogeneity and correlation parameters for each in-
dex test. To tackle parameter identifiability, we will make assump-
tions where necessary such as a common amount of between-study
heterogeneity in the sensitivity and specificity of all index tests,
and common correlation parameters. Any such assumptions will
be clearly stated and discussed. If between-study heterogeneity pa-
rameters cannot be estimated due to small numbers of studies, it
may be necessary to use a fixed-effect approach. To meet the inclu-
sion criteria, all studies must be performed in people with glioma,
and therefore are likely to also be performed in tertiary care. We
hope that this will reduce heterogeneity.
In addition to summary operating points, we will estimate dif-
ferences in sensitivity and differences in specificity between index
tests. We anticipate there will be very few direct comparative ac-
curacy studies (studies comparing the accuracy of two index tests
relative to a reference standard) (Takwoingi 2013), such that these
estimated differences will mostly be informed by ’indirect’ com-
parisons.
As described in Table 1, neither FISH nor PCR-based LOH as-
says are likely to be true ’gold standards’: each could in principle
lead to false-negative or false-positive test results. Treating these
tests as gold standards could therefore lead to biased estimates of
the sensitivity and specificity of all other tests. In our third set of
analyses, we will therefore apply latent class meta-analysis methods
(Chu 2009; Dendukuri 2012; Menten 2013; Sadatsafavi 2010;
Walter 1999). These methods provide estimates of sensitivity and
specificity based on a probabilistic definition of disease state. In
this modelling framework, the prevalence of 1p/19q codeletion
status among people with glioma in each study is treated as an
additional unknown parameter to be estimated. Latent class meta-
analysis methods have recently been used in a Cochrane Review
that aimed to determine the accuracy of the Xpert assay for di-
agnosing extrapulmonary tuberculosis and rifampicin resistance
(Kohli 2018).
While latent class analysis methods for a single study are well
documented, application in meta-analysis is still uncommon. It has
been shown that it is important to allow for tests being positively
correlated within disease states, usually referred to as ‘conditional
dependence’ (Vacek 1985). We will therefore use latent class meta-
analysis methods that allow for such conditional dependencies as
far as possible (Chu 2009; Dendukuri 2012; Sadatsafavi 2010).
The advantage of latent class methods is that they do not make
the unrealistic assumption that one of the tests is a gold standard.
However, in order to relax this assumption, it is usually neces-
sary to make some other assumptions. This is to avoid problems
with parameter identifiability (Jones 2010), which are introduced
by recognising that study-level prevalence and the sensitivity and
specificity of the ‘reference standard’ are all in fact unknown.
To reduce the number of parameters that need to be estimated, we
propose a priori that the following might be reasonable assump-
tions.
• That between-study heterogeneity parameters are shared
across tests. Informative prior distributions may be used to
constrain these heterogeneity parameters to be close to zero
(where zero corresponds to a fixed-effect model).
• That the correlation between the sensitivity and specificity
of any one test will be strongly negative. To aid parameter
identifiability, we will consider assuming that these correlations
are equal to -1.
• That people with concordant positive results with CGH,
SNP arrays, methylation arrays or NGS and FISH (with a cut-
off dependant on the percentage of cells with a 2:1 ratio) or any
other technique which confirms diploidy, are almost certainly
true positives. The rationale for this is that 100% specificity (no
false-positive results) would be expected if a test whose only
limitation is the inability to distinguish between absolute and
relative deletions (for example CGH, SNP arrays, methylation
arrays, NGS) were combined with a test which can detect
aneuploidy, for example FISH.
• That PCR-based LOH, RFLP, SNP arrays and NGS are
close to 100% sensitive (no false-negative results). False-negative
results on these tests can only be obtained if there is excessive
contamination of tumour samples with normal tissue. We will
assume that in a research context there is likely to be great care
taken to minimise the risk of contamination with normal tissue.
In formative prior distributions (e.g. a uniform (0.99, 1.00) prior
on sensitivity) might therefore be used to constrain the
sensitivity of these tests to be at least 99% in a research context.
• The errors in tests other than FISH and CISH may be
conditionally independent given the disease state. We believe it is
important to account for conditional dependence in FISH and
CISH results however, since these are very similar techniques.
If additional tests not already described are identified that have
been studied in a manner that fulfils our inclusion criteria, we will
consider (i) the potential ways in which false-positive and false-
7Diagnostic test accuracy and cost-effectiveness of tests for codeletion of chromosomal arms 1p and 19q in people with glioma (Protocol)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
negative results could occur, in order to assess whether the test
could be considered 100% sensitive or specific, and (ii) whether
the test can reasonably be considered conditionally independent
of other techniques given the disease state.
All statistical analyses will be carried out in the Bayesian statistical
software WinBUGS (Lunn 2000). We will assume multinomial
likelihoods for observed cross-classifications of test results, or bi-
nomial likelihoods for analyses assuming a perfect ‘gold standard’.
We will use vague prior distributions for parameters where pos-
sible. All prior distributions used will be stated, assumptions will
be clearly described and model code will be provided. For the la-
tent class analyses, we will extend WinBUGS code provided by
Menten 2008 for a single study to the multiple studies setting,
drawing on the methodological literature described above (Chu
2009; Dendukuri 2012; Sadatsafavi 2010).
A preliminary scoping search has identified 14 studies which have
compared results from two or more different techniques (Bigner
1999; Bouvier 2004; Burger 2001; Chaturbedi 2012; Clark 2013;
Harada 2011; Hatanpaa 2003; Jeuken 2006; Jha 2011; Lass 2013;
Natte 2005; Nigro 2001; Scheie 2006; Smith 1999). These may be
visualised as a network (see Figure 2). The only tests not included
in this network are RFLP, sequencing and methylation arrays as
no studies were identified in the scoping search that performed
these tests and another test on the same participants.
Figure 2. Network diagram for studies identified from scoping search
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The studies that we identified frequently presented results per per-
son on each test without designating which test should be consid-
ered the reference standard. In some studies, raw results (for ex-
ample PCR results from specific loci) rather than positive/negative
were presented, for example in Smith 1999. In these cases we will
contact authors to determine the cut-off which should be applied.
In cases where no response is obtained, we will consider applying
a threshold based on our own expertise, and if we are uncertain
about the appropriate threshold we will exclude the data. In other
studies it was clear that two different techniques had been applied
to samples from the same people but usable data were not pre-
sented, for example Franco-Hernandez 2009 and Molinari 2010).
Again, we will attempt to obtain raw data from the authors where
possible. Similarly, if more than two tests are compared and instead
of results for individual patients 2 x 2 tables for each comparison
of tests are reported, we will attempt to contact authors to obtain
individual patient data or fully cross-classified aggregate data. If
this is unsuccessful, we will attempt to make best use of the data
available.
Summary of findings for the DTA review
We will present the summary diagnostic accuracy results for each
test in a ’Summary of findings’ table, as illustrated in Table 2. We
will prefer results obtained from latent class analyses. Confidence
in each result will be assessed following the grades of recommen-
dation, assessment, development, and evaluation (GRADE) ap-
proach (Guyatt 2008). Guidance on the use of GRADE for diag-
nostic tests has been published (Schunemann 2008). We will rate
the overall strength of evidence as ’high’, ’moderate’, ’low’ or ’very
low’ considering risk of bias, imprecision, inconsistency, applica-
bility and publication bias, all of which may lead to downgrading
the quality of the evidence. See Appendix 3.
An issue when using GRADE to rate the quality of the evidence is
that test accuracy is considered a surrogate for outcomes that are
important to patients and can only provide indirect evidence of
impact on patient-important outcomes (Schunemann 2008). As
we described previously, the codeletion has diagnostic, prognostic
and predictive abilities in glioma, and all the tests described so far
will have the same risk of adverse events associated with the test
as they all require some biopsied tumour material. Therefore, we
will assume that testing using the most accurate test will improve
patient-important outcomes. We will use the indirectness domain
to downgrade the quality of the evidence if studies are found to
have low applicability to our review question using QUADAS-2.
We will also consider publication bias, but note that there is un-
certainty about the determinants of publication bias for diagnostic
accuracy studies and tests for detecting funnel plot asymmetry are
inadequate (Deeks 2005).
Investigations of heterogeneity
Investigations of heterogeneity planned for the DTA review
Where sufficient number of studies have assessed the same index
test, we will investigate the impact of the following index test
characteristics.
• Tumour sample type (i.e. FFPE or frozen tissues)
• Region(s) analysed
• Cut-off/threshold used to determine 1p/19q status
If sufficient studies are available, we will also investigate the effect
of the following population characteristics.
• Study prevalence of 1p/19q codeletion
• Tumour subtype and grade
Sensitivity analyses
Sensitivity analyses planned for the DTA review
As noted above, estimates of the differences in the sensitivity and
specificity of alternative tests will be informed by a mixture of
direct comparative studies (where available) and indirect evidence
through the network of test comparisons. Where possible, we will
perform sensitivity analyses restricting only to direct comparative
studies.
If sufficient data are available, we will also perform sensitivity
analyses by restricting analyses to studies judged not to be at high
risk of bias or low applicability.
Assessment of reporting bias
Assessment of reporting bias in the DTA review
Because of uncertainty about the determinants of publication bias
for diagnostic accuracy studies and the inadequacy of tests for de-
tecting funnel plot asymmetry (Deeks 2005), we will not perform
tests aimed at detecting publication bias.
Full integrated review of economic evidence and
economic model
Full integrated review of economic evidence
Characteristics and results of included economic evaluations will
be summarised using additional tables, supplemented by a narra-
tive summary that will compare and evaluate methods used and
principal results between studies. This includes the currency and
price year of costs, incremental cost and incremental cost-effec-
tiveness ratios. If it is not possible to express costs in this way,
then these results will be expressed as the most recent International
Dollars value using implicit price deflators for GDP and GDP
Purchasing Power Parities. Where possible, unit cost data will also
be combined and summarised (Shemilt 2011). This review will be
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conducted according to current guidance on the use of economics
methods in the preparation and maintenance of Cochrane reviews
(Shemilt 2011).
Economic model
The information extracted from the studies which are captured
as part of this review (from both the initial and economic search)
will be used to populate a decision analytic model. This model
will assess the cost-effectiveness of different methods of testing
for codeletion of chromosomal arms 1p and 19q in people with
glioma. The outcomes will be expressed as incremental cost per
true positive detected for each method. This model will include
participants over the age of 18 and the model will take an NHS
perspective. Parameter uncertainty will be addressed using a sen-
sitivity analysis.
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A D D I T I O N A L T A B L E S
Table 1. Techniques that can be used to detect 1p/19q codeletion and the theoretical ways false-positive and false-negative
results could be obtained.
Technique Brief description Potential ways false-positive re-
sults could be obtained
Potential ways false-negative re-
sults could be obtained
FISH FISH testing uses fluorescently-
labelled probes that are de-
signed to hybridise to specific
chromosomal locations. It can
be performed on formalin-fixed
and paraffin-embedded tissue
(FFPE), and on fresh or frozen
tissue. In this technique tissue
architecture is preserved
To test for chromosome 1p/
19q codeletion chromosomes
1 and 19 are analysed on
separate slides. FISH probes
corresponding to regions of
Focal deletions at regions that
the target probes hybridise to
could lead to false-positive re-
sults as these cannot be distin-
guished from whole arm dele-
tions (as only one probe per
chromosome arm is normally
used)
False-negative results could be
obtained if there has been a loss
of heterozygosity without copy
number reduction
13Diagnostic test accuracy and cost-effectiveness of tests for codeletion of chromosomal arms 1p and 19q in people with glioma (Protocol)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 1. Techniques that can be used to detect 1p/19q codeletion and the theoretical ways false-positive and false-negative
results could be obtained. (Continued)
1p or 19q labelled using one
colour, and control probes on
1q or 19p labelled in another
colour (as 1q and 19p seem
to remain unaffected) are used.
Many commercially available
probes hybridise to loci at 1p36
and 19q13, although the FISH
probes used at different centres
may not target exactly the same
loci (Pinkham 2015).
Normal nuclei show a diploid
signal ratio of 2/2 (two signals
from 1p or 19q and two signals
from 1q or 19p). Absolute dele-
tions will theoretically result in
1 signal from 1p or 19q in the
presence of two signals from the
control loci
There is no consensus on cut-
offs to diagnose codeletion.
This is demonstrated by the fact
that the EORTC study 26951
and the RTOG study 9402
used slightly different criteria
(Pinkham 2015). Some labo-
ratories define cut-offs based
on the percentage of cells with
deleted and imbalanced signals,
some define cut-offs based on
ratios calculated by dividing the
total number of test probes by
the total number of control
probes, and some combine per-
centage and ratio cut-offs
Depending on the way that
deletions are diagnosed (i.e. the
cut-off used and whether it de-
pends on the ratio of test probes
to control probes), aberrations
that lead to disproportionate
gain in control probe loci (i.e.
1q and 19p) could lead to false-
positive results
False-negative results could be
obtained if non-neoplastic nu-
clei are assessed
The way that the tumour tis-
sue is sectioned to prepare it for
FISH could lead to ‘truncation
artefact’. Nuclei may be tran-
sected which may lead to them
containing incomplete genetic
material. Fals- positive results
may be obtained from normal
tissue in the presence of exces-
sive truncation artefact
Excessive truncation artefact in
neoplastic tissue could lead to
false-negative results
CISH This is a very similar technique
to FISH, but instead of using
fluorescent labelling, the probes
are labelled with a marker such
as biotin, digoxigenin or dini-
trophenyl, and then this marker
is detected using antibodies or
streptavidin (that binds biotin)
that is conjugated to enzymes
such as horseradish peroxidase
or alkaline phosphatase. The
presence of the probe can then
As for FISH. As for FISH.
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Table 1. Techniques that can be used to detect 1p/19q codeletion and the theoretical ways false-positive and false-negative
results could be obtained. (Continued)
be visualised in the presence
of a substrate that undergoes a
colour change in the presence of
the enzyme
The advantages of CISH is that
it does not require a fluores-
cence microscope and staining
is permanent
PCR-based LOH assays This technique analyses poly-
morphic microsatellites that
are dispersed throughout the
genome. Different alleles have
different numbers of repeats.
PCR amplification of regions
containing polymorphic mi-
crosatellites can therefore result
in different length PCR prod-
ucts. If an individual is het-
erozygous (has two different al-
leles) for a microsatellite, PCR
of this region will result in
two different length products. If
heterozygosity is lost, only one
length product will be obtained.
An individual must be heterozy-
gous for a microsatellite for it to
be informative, and DNA from
normal tissue is required to de-
termine this. LOH can be de-
termined by comparing the ra-
tio of PCR products of differ-
ent lengths obtained from nor-
mal and tumour tissue
Primers that amplify regions
containing microsatellites on
1p and 19q can be used to de-
termine whether 1p and 19q are
codeleted. However, there is no
consensus on location or num-
ber of microsatellites analysed
PCR cannot distinguish be-
tween relative and absolute
deletions, so people with rela-
tive deletions will be given false-
positive results
If tumour samples are heavily
contaminated with normal tis-
sue, PCR products for both al-
leles will be obtained in a ratio
that would give a false-negative
result
Depending on primer spacing
and the number of informa-
tive loci, the technique may de-
tect focal rather than whole arm
deletions
Imbalanced polysomy, for ex-
ample gain of one copy of chro-
mosome 1 and 19, may result in
allelic imbalance and be inter-
preted as loss of heterozygosity
RFLP analysis LOH can also be detected us-
ing RFLP analysis. In RFLP
restriction enzymes that recog-
nise specific sequences are used
to cut DNA, resulting in frag-
ments of specific sizes. Differ-
ent alleles may contain cut sites,
Cannot distinguish between
relative and absolute deletions,
so people with relative deletions
will be given false-positive re-
sults
If tumour samples are heavily
contaminated with normal tis-
sue, digestion products for both
alleles will be obtained in a ratio
that would give a false-negative
result
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Table 1. Techniques that can be used to detect 1p/19q codeletion and the theoretical ways false-positive and false-negative
results could be obtained. (Continued)
or the DNA fragment that the
restriction enzyme produces af-
ter digestion may be expected
to differ due to different num-
bers of repeats in different alle-
les. Therefore, in a similar man-
ner to PCR, LOH can be de-
tected through loss of fragments
of a specific size from informa-
tive loci (where an individual is
heterozygous in normal tissue)
Depending on the regions anal-
ysed, it is possible that this tech-
nique may detect focal rather
than whole arm deletions
Imbalanced polysomy, for ex-
ample gain of one copy of chro-
mosome 1 and 19, may result in
allelic imbalance and be inter-
preted as loss of heterozygosity
Comparative quantitative PCR Comparative quantitative PCR
compares the amount of PCR
product obtained from 1p/19q
with PCR product obtained
from other chromosomal re-
gions. If a deletion is present,
less PCR product will be ob-
tained. This technique has the
advantages that heterozygosity
at loci is not required, nor a
sample of normal tissue
PCR cannot distinguish be-
tween absolute deletion and rel-
ative deletions in the presence
of polyploidy (i.e. those dele-
tions that would give a 2:4 ra-
tio/equivalent with FISH)
If tumour samples are heavily
contaminated with normal tis-
sue the amount of PCR prod-
uct obtained would result in a
false-negative result
Polysomy which causes the
PCR product from control re-
gions to increase could result in
false-positive results
False-negative results could be
obtained if there has been a
LOH without copy number re-
duction
Aneuploidy which causes the
PCR product from control re-
gions to decrease could result in
false-negative results
MLPA MLPA uses probes designed to
hybridise to specific regions of
the genome that have been split
into two. Each probe “half ” also
contains sequences correspond-
ing to universal forward and
reverse binding sites for PCR
primers, and one “half ” con-
tains a region of varying length
to help identify the probe later
The primers are hybridised to
denatured sample DNA (for ex-
ample from a tumour). The
next step is ligation. Only probe
Cannot distinguish between ab-
solute deletion and relative
deletions in the presence of
polyploidy (i.e. those deletions
that would give a 2:4 ratio/
equivalent with FISH)
If tumour samples are heavily
contaminated with normal tis-
sue, a false-negative result may
arise
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Table 1. Techniques that can be used to detect 1p/19q codeletion and the theoretical ways false-positive and false-negative
results could be obtained. (Continued)
halves which are hybridised
to adjacent sequences on the
sample DNA will be ligated
together. PCR, using primers
corresponding to the universal
binding sides contained in the
probes, is used to amplify the
probes. Only those probe halves
which were ligated together will
be amplified to any extent, as
it is only these products which
contain the binding sites for
both the forward and reverse
PCR primers
The PCR products can then be
separated by length, and quan-
tified. The results are then nor-
malised internally (by compar-
ing reference probes with tar-
get probes), and then com-
pared with reference samples.
Heterozygous deletions can be
identified as a probe ratio of 0.5
will be observed, and heterozy-
gous duplications from a probe
ratio of 1.5. Usually, probe ra-
tios below 0.7 or above 1.3 are
regarded as indicative of a het-
erozygous deletion (copy num-
ber change from two to one al-
lele) or duplication (copy num-
ber change from two to three al-
leles), respectively (Eijk-Van Os
2011).
Single nucleotide polymor-
phisms at primer binding sites,
as single mismatches at ligation
sites can inhibit ligation
False-negative results could be
obtained if there has been a
LOH without copy number re-
duction
CGH In CGH differentially-labelled
genomes from the tumour (the
test genome) and normal tis-
sue (the control genome, which
does
not need to be from the same
person) are simultaneously hy-
bridised to normal metaphase
chromosomes. Changes in copy
number, caused for example by
loss or gain of regions, will alter
the ratio of the two genomes.
If two different fluorochromes
Cannot distinguish between ab-
solute deletion and relative
deletions in the presence of
polyploidy (i.e. those deletions
that would give a 2:4 ratio/
equivalent. with FISH)
If tumour samples are heavily
contaminated with normal tis-
sue, a false-negative result may
arise
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Table 1. Techniques that can be used to detect 1p/19q codeletion and the theoretical ways false-positive and false-negative
results could be obtained. (Continued)
are used to mark the genomes
(or detect the labels), changes
in copy number can be revealed
from the relative intensities of
fluorochromes used to detect
the two genomes. CGH detects
DNA sequence copy number
changes relative to the average
copy number in the entire tu-
mour sample. However, signals
can be normalised using the sex
chromosomes which may help
if a tumour is known to be nor-
mal for these chromosomes
False-negative results could be
obtained if there has been a
LOH without copy number re-
duction
aCGH aCGH follow the same prin-
ciples as CGH, but instead of
the two genomes being compet-
itively hybridised to metaphase
chromosomes, they are hy-
bridised to a microarray. The
theoretical resolution of aCGH
is greater than that of traditional
CGH
As for CGH As for CGH
SNP arrays A SNP array is a kind of DNA
microarray. SNP arrays allow
both copy number status and
genotype to be determined, al-
lowing detection of both losses
and copy-neutral LOH
SNPs are variations at a single
position in a DNA sequence.
Since individuals usually inherit
one copy of each SNP position
from each parent, the individ-
ual’s genotype at a SNP site is
typically either AA, AB or BB.
To detect abnormalities using
SNP arrays, sample DNA is
fragmented, labelled and hy-
bridised to an array contain-
ing immobilised allele-specific
oligonucleotide probes (one
probe for each allele). The sig-
nal intensity associated with
each probe is then measured.
Copy number changes can be
Cannot distinguish between ab-
solute deletion and relative
deletions in the presence of
polyploidy arising from whole
genome duplication after the
codeletion event (i.e. those dele-
tions that would give a 2:4 ra-
tio/equivalent with FISH)
If tumour samples are heavily
contaminated with normal tis-
sue, a false-negative result may
arise
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Table 1. Techniques that can be used to detect 1p/19q codeletion and the theoretical ways false-positive and false-negative
results could be obtained. (Continued)
detected from the intensity of
signal. By comparing the result
for each SNP with those from
normal tissue, or by using a hid-
den Markov model, LOH can
be detected
In the rare case of 2:
2 tetraploidy, it is possible that
SNP arrays will not be able to
distinguish absolute from rela-
tive deletions
Methylation arrays Genome-wide DNA methyla-
tion array data can also be used
to detect 1p/19q status, as re-
ported in Capper 2018.
In methylation arrays, specific
regions of the genome that may
be modified by methylation are
investigated. The array has two
probes for each region, one for
the methylated and one for
unmethylated. To detect copy
number variations the signal
from both probes (the methy-
lated and unmethylated) for a
specific region are added to-
gether and compared with a ref-
erence genome
Cannot distinguish between ab-
solute deletion and relative
deletions in the presence of
polyploidy arising from whole
genome duplication after the
codeletion event (i.e. those dele-
tions that would give a 2:4 ra-
tio/equivalent with FISH)
If tumour samples are heavily
contaminated with normal tis-
sue, a false-negative result may
arise
False-negative results could be
obtained if there has been a
LOH without copy number re-
duction





Whilst traditional Sanger se-
quencing sequences a single
DNA sequence, NGS is capa-
ble of sequencing multiple se-
quences simultaneously
Techniques have been devel-
oped to detect LOH and copy
number variations using NGS.
Deletions can be detected by
relative perturbations in the
read depth
LOH can be detected when the
ratio of alleles at a heterozygous
SNP site is perturbed
Cannot distinguish between ab-
solute deletion and relative
deletions in the presence of
polyploidy arising from whole
genome duplication after the
codeletion event (i.e. those dele-
tions that would give a 2:4 ra-
tio/equivalent with FISH)
If tumour samples are heavily
contaminated with normal tis-
sue, a false-negative result may
arise
19Diagnostic test accuracy and cost-effectiveness of tests for codeletion of chromosomal arms 1p and 19q in people with glioma (Protocol)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
aCGH: array comparative genomic hybridization; CGH: comparative genomic hybridization; CISH: chromogenic in situ hybridization;
FFPE: formalin-fixed and paraffin-embedded tissue; FISH: fluorescence in situ hybridization; LOH: loss of heterozygosity; MLPA:
multiplex-ligation-dependent probe amplification; NGS: next-generation sequencing; PCR: polymerase chain reaction; RLFP:
restriction fragment length polymorphism; SNP: single nucleotide polymorphism.
Table 2. Proposed ’Summary of findings’ table





Accuracy What do the results
mean?







of X%, X people
out of 100 with
glioma will have
a 1p/19q codele-
tion. Of the X peo-
ple with a 1p/19q
codeletion Y peo-
ple will be given
the correct positive
result and Z peo-
ple will be given
a false-negative re-
sult. Of the 100-X
people without the
codeletion, A peo-
ple will be given
a correct negative
result and B peo-
ple will be given a
false-positive result
CI: confidence interval.
20Diagnostic test accuracy and cost-effectiveness of tests for codeletion of chromosomal arms 1p and 19q in people with glioma (Protocol)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A P P E N D I C E S
Appendix 1. Database search strategies
In this review we aim to include all tests for 1p/19q codeletion which have been studied comparatively, and consequently have not got
a pre-defined list of eligible index tests. We have therefore decided to focus the search strategy based on the population (people with
glioma) and the target condition (codeletion of chromosomes 1 and 19).
Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily <1946 onwards>
1. exp glioma/
2. (glioma* or astrocytoma* or astroblastoma* or ependymoma* or subependymoma* or oligodendroglioma* or oligoastrocytoma*
or pleomorphic xanthoastrocytoma* or glioblastoma* or GBM* or ganglioglioma* or gliosarcoma* or gangliocytoma* or ((glial* or
glioneuronal* or brain*) and (tumor* or tumour* or cancer* or neoplasm*))).mp.
3. 1 or 2
4. Chromosomes, Human, Pair 1/ or (chromosome 1 or 1p).mp.
5. Chromosomes, Human, Pair 19/ or (chromosome 19 or 19q).mp.
6. (1p?19q* or “1p/19q” or (1p* adj3 19q*)).mp.
7. 4 and 5
8. 6 or 7
9. 3 and 8
Ovid Embase <1974 onwards>
1. exp glioma/
2. (glioma* or astrocytoma* or astroblastoma* or ependymoma* or subependymoma* or oligodendroglioma* or oligoastrocytoma*
or pleomorphic xanthoastrocytoma* or glioblastoma* or GBM* or ganglioglioma* or gliosarcoma* or gangliocytoma* or ((glial* or
glioneuronal* or brain*) and (tumor* or tumour* or cancer* or neoplasm*))).mp.
3. 1 or 2
4. Chromosome 1/ or chromosome 1p/ or (chromosome 1 or 1p).mp.
5. chromosome 19/ or chromosome 19q/ or (chromosome 19 or 19q).mp.
6. 4 and 5
7. (1p?19q* or “1p/19q” or (1p* adj3 19q*)).mp.
8. 6 or 7
9. 3 and 8
BIOSIS Citation Index <1969 onwards>
#1 TS=(glioma* or astrocytoma* or astroblastoma* or ependymoma* or subependymoma* or oligodendroglioma* or oligoastrocytoma*
or pleomorphic xanthoastrocytoma* or glioblastoma* or GBM* or ganglioglioma* or gliosarcoma* or gangliocytoma* or ((glial* or
glioneuronal* or brain*) and (tumor* or tumour* or cancer* or neoplasm*)))
#2 TS=(1p*19q* OR “1p/19q”)
#3 TS=((“chromosome 1” OR 1p) AND (“chromosome 19” OR 19q))
#4 #2 or #3
#5 #1 and #4
WHO International Clinical Trials Registry Platform (ICTRP)
Results from each of the following search lines will be downloaded and de-duplicated in EndNote:
Search 1: 1p* and 19q*
Search 2: 1p19q or 1p/19q
Search 3: glioma* and diagnostic test or astrocytoma* and diagnostic test or astroblastoma* and diagnostic test or ependymoma* and diagnostic
test or subependymoma* and diagnostic test or oligodendroglioma* and diagnostic test or oligoastrocytoma* and diagnostic test or pleomorphic
xanthoastrocytoma* and diagnostic test or glioblastoma* and diagnostic test or GBM* and diagnostic test or ganglioglioma* and diagnostic test
or gliosarcoma* and diagnostic test or gangliocytoma* and diagnostic test or glial tumor* and diagnostic test or glial tumour* and diagnostic test
or glial cancer* and diagnostic test or glial neoplasm* and diagnostic test or glioneuronal tumor* and diagnostic test or glioneuronal tumour*
and diagnostic test or glioneuronal cancer* and diagnostic test or glioneuronal neoplasm* and diagnostic test or brain tumor* and diagnostic
test or brain tumour* and diagnostic test or brain cancer* and diagnostic test or brain neoplasm* and diagnostic test
Search 4: glioma* and diagnostic assessment or astrocytoma* and diagnostic assessment or astroblastoma* and diagnostic assessment or
ependymoma* and diagnostic assessment or subependymoma* and diagnostic assessment or oligodendroglioma* and diagnostic assessment or
oligoastrocytoma* and diagnostic assessment or pleomorphic xanthoastrocytoma* and diagnostic assessment or glioblastoma* and diagnostic
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assessment or GBM* and diagnostic assessment or ganglioglioma* and diagnostic assessment or gliosarcoma* and diagnostic assessment or
gangliocytoma* and diagnostic assessment or glial tumor* and diagnostic assessment or glial tumour* and diagnostic assessment or glial cancer*
and diagnostic assessment or glial neoplasm* and diagnostic assessment or glioneuronal tumor* and diagnostic assessment or glioneuronal
tumour* and diagnostic assessment or glioneuronal cancer* and diagnostic assessment or glioneuronal neoplasm* and diagnostic assessment
or brain tumor* and diagnostic assessment or brain tumour* and diagnostic assessment or brain cancer* and diagnostic assessment or brain
neoplasm* and diagnostic assessment or brainstem tumor* and diagnostic assessment or brainstem tumour* and diagnostic assessment or
brainstem cancer* and diagnostic assessment or brainstem neoplasm* and diagnostic assessment
Search 5: glioma* and DTA or astrocytoma* and DTA or astroblastoma* and DTA or ependymoma* and DTA or subependymoma* and
DTA or oligodendroglioma* and DTA or oligoastrocytoma* and DTA or pleomorphic xanthoastrocytoma* and DTA or glioblastoma* and
DTA or GBM* and DTA or ganglioglioma* and DTA or gliosarcoma* and DTA or gangliocytoma* and DTA or glial tumor* and DTA or
glial tumour* and DTA or glial cancer* and DTA or glial neoplasm* and DTA or glioneuronal tumor* and DTA or glioneuronal tumour*
and DTA or glioneuronal cancer* and DTA or glioneuronal neoplasm* and DTA or brain tumor* and DTA or brain tumour* and DTA or
brain cancer* and DTA or brain neoplasm* and DTA or brainstem tumor* and DTA or brainstem tumour* and DTA or brainstem cancer*
and DTA or brainstem neoplasm* and DTA
Appendix 2. Review-specific tailoring of QUADAS-2
Domain 1: Patient selection
Risk of bias
Was a consecutive or random sample of patients enrolled?
Yes: If a consecutive sample or a random sample of eligible participants was included in the study
No: If a non-consecutive sample or a non-random sample of eligible participants was included in the study
Unclear: If it is not clear whether a consecutive sample or a random sample of eligible participants was included in the study
Was a case-control (or ‘two-gate’) design avoided?
Yes: If the study had a single set of inclusion criteria
No: If the study had more than one set of inclusion criteria
Unclear: If the inclusion criteria for the study are not clear
Did the study avoid inappropriate exclusions?
Yes: If all patients with glioma were included
No: If a subset of patients with glioma were excluded due to sub-classification/severity of glioma
Unclear: If the inclusion criteria for the study are not clear
Overall: Could the selection of patients have introduced bias?
We will take highest concern from any individual signalling question as our overall judgement (i.e. risk of bias will be classified as low
if the response to all three questions is ‘yes’; high if the response to any question is ‘no’; and unclear if the response to any question is
‘unclear’ and the criteria for high risk of bias are not fulfilled).
Applicability
Are there concerns that the included patients do not match the review question?
High: If the study population included patients who would not have undergone testing in real practice, for example healthy controls.
Low: If the study included only a clinically relevant population that would have undergone testing in real practice
Unclear: If the inclusion criteria for the study are not clear
Domain 2: Index test
Risk of bias
Were the index test results interpreted without knowledge of the results of the other tests being compared?
Yes: If the index test is objective or if subjective if interpreted without the knowledge of the results of other tests for 1p/19q codeletion.
The first test to be interpreted will be judged to be interpreted without knowledge of the results of the other tests even if it is not
explicitly reported that it was interpreted ’blind’ or without the knowledge of other test results
No: If test is subjective and interpreted with the knowledge of the results of other tests for 1p/19q codeletion
Unclear: If the test is subjective and it was unclear whether it was interpreted with the knowledge of other tests for 1p/19q codeletion
If a threshold was used, was it prespecified?
Yes: If the definition of what was considered to be a positive test result was defined before testing was performed
No: If the definition of what was considered to be a positive test result was defined after testing was performed and based on the results
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Unclear: If it was unclear whether the definition of what was considered to be a positive test result was defined before testing was
performed
Overall: Could the conduct or interpretation of the index test have introduced bias?
We will take highest concern from any individual signalling question as our overall judgement.
Applicability: Are there concerns that the index test, its conduct, or its interpretation differ from the review question?
High: If there are concerns that the index test, its conduct, or its interpretation differ from the review question
Low: If there are no concerns that the index test, its conduct, or its interpretation differ from the review question
Unclear: If the description of the index test is inadequate
Domain 3: Reference standard
We envisage that many studies will have compared two or more tests without necessarily designating a reference standard.
In addition, as we are planning to perform a latent class analysis, which allows for an imperfect reference standard, the risk of bias
signalling question regarding whether the reference standard is likely to correctly classify the target condition can be omitted.
We have also decided that the applicability question is not relevant.
We have therefore decided to complete domain 2 for each test that has been compared.
Domain 4: Flow and timing
We have modified some of the wording of the signalling questions to reflect the fact that studies may not have designated a reference
standard, and that this is not an issue for our latent class analysis.
Risk of bias
Was there an appropriate interval between the tests being compared?
We envisage that most tests will be done on biopsied material.
Yes: If all tests were performed on biopsied tumour material collected on one occasion
No: If test were performed on tumour material collected at different time points
Unclear: If it is unclear whether the tests were performed on the same material.
Were all patients included in the analysis?
Yes: If all participants were included in the analysis, or if participants were excluded because they did not meet inclusion criteria or if
withdrawals were less than 5% of the enrolled population (arbitrarily selected cut-off )
No: If any participants were excluded from the analysis because of uninterpretable results, because of inability to undergo index test or
reference standard or for unclear reasons
Overall: Could the patient flow have introduced bias?
We will take highest concern from any individual signalling question as our overall judgement.
Appendix 3. Domains to be considered when judging the strength of the body of evidence
Domains to be considered when judging the strength of the body of evidence, based on GRADE.
Domain Explanation
Risk of bias Based on results of risk of bias assessments. Confidence in the evidence base will be downgraded if most of the
evidence is from studies not judged to be at low risk of bias
Imprecision Confidence in the evidence base will be downgraded if the estimate of the effect size from a meta-analysis is not
precise, or, if no meta-analysis is performed, if the estimate of the size of effect from individual studies is not precise
Inconsistency Confidence in the evidence base will be downgraded if there is unexplained heterogeneity or variability in results
across studies
Indirectness Based on QUADAS-2 assessments of applicability. Confidence in the evidence base will be downgraded if most
of the evidence is from studies judged to have low applicability to the review question
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(Continued)
Publication bias Confidence in the evidence base will be downgraded if we uncover evidence of publication bias
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